content_image/257525.jpg content_image/257524.jpg
## L Review of Global Operations 

Japan 

We will launch a steady stream of new products as we push ahead to become the leader in Japan in terms of quantity and quality. 

<img src='content_image/257525.jpg'>

<img src='content_image/257524.jpg'>

Note: Yen base 

*Calculated according to the location of sellers 

*IFRS 

Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales including revenues related to export products and licenses, etc. in Japan decreased by 1.2% year on year to ¥550.7 billion. Sales in the Japanese market were ¥535.6 billion, mostly unchanged from the previ- ous fiscal year, as the impact of generics was largely offset by steady expansion in sales of growing mainstay products and new products. 

By product, growing sales of Betanis contributed with Vesicare to the further expansion of our share of the overactive bladder (OAB) treatment market. In addition to Betanis, products such as Micardis (including its combination drugs, Micombi and Micamlo), Celecox, Symbicort, Bonoteo and vaccines showed growth in sales. There were also contributions from sales of new products including Cimzia and Gonax. Sales of some prod- ucts declined, including Lipitor, Seroquel and Myslee, mainly due to the impact of generics. Micamlo BP, Acofide, Bisono Tape and Irribow OD were launched in fiscal 2013. 

Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. For fiscal 2014, we project a 0.4% year-on-year decrease in domestic sales to ¥528.4 billion. This estimate includes only a slight fall in sales in Japan’s prescription market to ¥508.3 billion, as the impact of NHI drug price revisions are expected to be offset partly by sales of growing prod- ucts and new products. We expect sales contributions from Suglat and XTANDI, which were launched in April and May 2014, respectively. 

